Moderna Inc raised its full-year sales forecast for its COVID-19 vaccine to around $21 billion from $19 billion on Thursday.

In February, the company forecasted $19 billion in sales from signed contracts, with an option for an additional $3 billion in purchases.

On Thursday, Moderna forecasted another $500 million in purchases.